IV-255

• Description:

  IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345) . IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide[1].

• UNSPSC:

  12352005

• Target:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/iv-255.html

• Purity:

  98.41

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  COC1=CC=C(N2[C@H]3CN([C@@H](C2)C3)C(NC4=CC(F)=C(C=C4)F)=O)C=C1

• Molecular Formula:

  C19H19F2N3O2

• Molecular Weight:

  359.37

• References & Citations:

  [1]Yang C, et al. Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma. J Cell Mol Med. 2023 Sep;27 (18) :2770-2781.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported